Investment Theme
Life Science Tools
Research platforms, laboratory automation, and the software and hardware that make drug discovery and development faster, cheaper, or more reliable.
The Space
Tools companies sell to the same industry ChaosBio comes from, which makes this one of the more legible categories to underwrite: the question is usually not whether the problem is real — anyone who has run a discovery program has felt it — but whether the product is differentiated enough, and the go-to-market realistic enough, to build a durable business rather than a feature.
The best tools companies solve a problem the founder has personally been burned by, and can describe exactly which workflow gets faster, cheaper, or more reliable, and by how much.
Why It Matters
The gap between promising and investable.
A platform or piece of lab automation has to compete for a customer’s attention against "just hire another scientist" or "just keep doing it the old way," which is a lower bar to clear scientifically but a real one commercially.
The founders worth backing here usually have direct experience of the exact bottleneck they are removing, which is what lets them sell into a skeptical R&D buyer rather than around one.
The ChaosBio Lens
What ChaosBio looks for.
Applied to every life science tools opportunity ChaosBio reviews, alongside the general investment framework.
Real workflow displacement
Does this replace or meaningfully accelerate a specific, named step in a research or development workflow, not a vague productivity claim?
Differentiation and defensibility
What stops an existing lab-tools incumbent from adding this capability, and what happens to the business if they do?
Adoption path
Is there a credible route into research and development organizations — pilot, procurement, and budget owner — or is the go-to-market still theoretical?
Unit economics
Does the pricing and cost structure work at the scale the business plan assumes, not only at pilot volume?
Related Reading
From the Journal.
See life science tools opportunities as they come in.
Join the Investor Network for curated life science tools and other early-stage life sciences opportunities, reviewed through the ChaosBio investment framework. Free, and no obligation to invest.